Lyell Immunopharma (LYEL) Liabilities and Shareholders Equity (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $350.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 18.42% year-over-year to $350.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 32.36% YoY), and the FY2025 full-year result was $340.1 million, down 30.72% from the prior year.
• Liabilities and Shareholders Equity grew to $350.6 million in Q1 2026, from $340.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q1 2022 to a low of $340.1 million in Q4 2025.
• A 5-year average of $684.8 million and a median of $694.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity declined 16.84% in 2022 and plunged 41.08% in 2025, its largest moves.
• Tracing LYEL's Liabilities and Shareholders Equity over 5 years: stood at $937.6 million in 2022, then decreased by 20.0% to $750.0 million in 2023, then slumped by 34.55% to $490.9 million in 2024, then tumbled by 30.72% to $340.1 million in 2025, then climbed by 3.11% to $350.6 million in 2026.
• Business Quant data shows LYEL's Liabilities and Shareholders Equity at $350.6 million in Q1 2026, $340.1 million in Q4 2025, and $408.0 million in Q3 2025.